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Low-grade inflammatory state causes the development of the principal chronic-degenerative pathologies related
with ageing. Consequently, it is required a better comprehension of the physiologic origins and the consequences
of the low-grade inflammatory state for the identification of 1) the basic mechanisms that lead to the chronic
inflammatory state and, after that, to the progression toward the pathologies and 2) the parallel identification of
the prognostic biomarkers typical of these passages. These biomarkers could bring to several improvements in the
health quality, allowing an early diagnosis and more effective treatments for: a) the prevention strategies on the
healthy population, to assure a healthy longevity and b) the identification of personalized treatment in patients, to
assure the benefit of the therapy. For the identification of these biomarkers it is necessary to consider that the
ageing processes produce alterations of the physiologic systems and that these modifications compromise the
communications between these networks: this state constitutes an obstacle for an appropriate physiologic
homeostasis, that plays a fundamental role for the safeguard of the health. It is also to be considered that immune
senescence affects both men and women, but it does it in different ways: a sexual dimorphism of immune
pathways in the setting of immune response homeostasis is normally present, as we previously underlined.
Therefore we hypothesize that, in order to prevent the development of the chronic-degenerative pathologies
related with ageing, it is important to identify "Biomarkers of Homeostasis " specific for each gender: these are
biologic molecules that should be measurable in a practical and no-invasive way and whose variations can
quantify the male and female risk of losing the physiologic system homeostatic capacity. This competence is not
only critical in the control of inflammation, but it is also prognostic for the passages from low-grade inflammatory
state to the chronic inflammation and to the progression toward the degenerative pathologies. Beginning from
the actual results, our intent is 1) to discuss and underline the importance of these new research perspectives in
the definition of ageing gender-specific clinical "Biomarkers of Homeostasis" and 2) to propose homeostasis
biomarkers, already present in the research results.
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Figure 2 Prognostic biomarkers could be suitable as risk
indicator of pathologies and of the clinic/therapeutic trend. The
recent developments in the research, in particular in genetic, in
proteomic and in informatics areas, are leading to the discovery of
prognostic biomarkers that could be suitable as risk indicator of
pathologies and of the clinic/therapeutic trend. The transport in the
clinical practice of these biomarkers allows the early diagnosis and
personalized therapeutic intervention, contributing, then, not only to
the improvement in the health quality but also to a better
administration of the sanitary system.
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Mean age and lifespan are progressively growing and the
increase of elderly population is related with a parallel
rise of subjects with chronic inflammation and chronic-
degenerative diseases (Figure 1) as neoplastic, autoimmune
and neurodegenerative pathologies: it constitutes a chal-
lenge for the administration of the health system [1].
The difficulties in the administration of the chronic-
degenerative diseases are related with the difficulties in
the prevention and in the treatment of these pathologies:
their diagnosis is arduous as the identification of a cor-
rect therapeutic line and, moreover, they absorb an
increasing rate in the financial statements of the health
assistance of the whole world, determining economic,
social, biomedical and political problems [2].
The recent developments in the research are leading
to the discovery of prognostic biomarkers that could be
suitable as risk indicator of pathologies and of the clinic/
therapeutic trend (Figure 2). The transport in the clinical
practice of these biomarkers allows an early diagnosis
and personalized therapeutic interventions, contributing,
then, not only to the improvement in the health quality,
but also to a better administration of the sanitary
system.
The prognostic biomarker is, then, a biologic high-
lighter that in clinical practice indicate 1) the risk ofFigure 1 Progressive increase of the elderly population:
parallel increase of the subjects with chronic inflammation and
chronic-degenerative diseases. The mean age and the lifespan are
progressively growing and this increase of the elderly population is
related with a parallel increase of the subjects with chronic
inflammation and chronic-degenerative diseases as neoplastic,
autoimmune and neurodegenerative pathologies.contracting a specific pathology, 2) the state of its
progression and 3) the relative risk/benefit related
with the specific therapy, exerting a central role in
the selection of the most effective treatment. For these
reasons, prognostic biomarkers have a significant role in
clinical practice in which they are determining relevant
progresses.
These progresses could be principally synthetized in
the passage of the modern medicine from a generalized
system, in which the therapy is the same for all the
patients with the same disease, to a stratified organization,
in which patients are subdivided in clinical/therapeutic
subgroups, or, even better, to a personalized one, in which
the treatment is defined on the specific physiologic char-
acteristics of the single subject. This concept has relevant
implication in clinical practice, thanks to the possibility of
modern medicine, both stratified and personalized, to link
the survey of a specific prognostic biomarker to a specific
pathology and to its related therapeutic risk/benefit ratio
(Figure 2).
For this success, however, it is necessary to define suit-
able prognostic biomarkers, with a real disease predictive
power that could be used to better define translational
protocols in the routine clinical practice. They have to
be detectable in a no-invasive and early way in rela-
tionship with the output. It is clear at this point that the
definition of these biomarkers constitutes a clinical and
Berghella et al. Immunity & Ageing 2014, 11:3 Page 3 of 16
http://www.immunityageing.com/content/11/1/3social necessity and it is an important competence of the
scientific research in this area.Figure 3 Ageing research data identify the incapacity to
preserve health in the loss of homeostasis. Changes of the
physiologic functions related with the ageing process obstacle anPresentation of the hypothesis
The definition of these biomarkers is currently possible,
thanks to new technologies that allow us to reveal the
complexity of the biology of our physiologic (the normal
health state) and pathologic (disease states) systems: in
this way it is possible to select the biomarkers that are
significant for the clinical monitoring of the two states,
physiologic and pathologic.
Being an appropriate physiologic homeostasis essential
for the health safeguard, we can define these clinical bio-
markers thanks to the above mentioned procedures and
studying the homeostatic state: 1) the homeostatic bal-
ance of the biologic system in the healthy state (the bio-
markers of the physiologic state) and 2) the loss of this
homeostasis in the pathological ones (the biomarkers of
the pathological degeneration and of its progression).appropriate physiologic homeostasis, impeding health safeguard:
they affect all the cells and in particular the nervous, endocrine,
immune ones, compromising the functioning of these fundamental
regulatory system and their mutual communication.Research perspectives for the definition of clinical
"Biomarkers of Homeostasis”: for early diagnosis and
more effective treatments in the ageing related
chronic-degenerative diseases
There are two essential points that give support to these
new research perspectives:
1) Changes of the physiologic functions related with
the ageing process obstacle an appropriate
physiologic homeostasis (Figure 3), impeding in this
way the health safeguard: they affect all the cells and
in particular the nervous, endocrine, immune ones,
compromising the functioning of these fundamental
regulatory systems and their mutual communication
[3-6].
2) Numerous studies are underlining a strong
relationship between the inflammatory mediators
and the ageing-related diseases [1] (Figure 1), as
cardiovascular pathologies and Alzheimer, and they
show that genetically predisposed individuals that
are able to control inflammatory activity have a
reduced possibility to develop inflammatory
ageing-related diseases, having a greater chance
to become centenary [7-11].
Inflammation is a complex process that involves wide-
spread changes in cellular and molecular components of
physiology. Although controlled inflammation is a ne-
cessary process that is required for an array of processes
including tissue repair, wound healing and for defence
against invading foreign pathogens, chronic and uncon-
trolled inflammation is harmful and has now been linked
to a number of human ailments [12,13] (Figure 1).Different studies show that a “low grade systemic
inflammation” characterizes ageing [1] and that inflam-
matory biomarkers are significant prognostic indices of
mortality in elderly subjects [1,14-16]: The low grade
systemic inflammation is involved in different biologic
mechanisms that are responsible for the decline of the
physical function and for the age related pathologies as
Alzheimer or atherosclerosis that origin and progress
thanks to this type of inflammatory state [1,7,8,16-18]. A
large class of factor, as smoke, infections, obesity, genetic
and the decrease of the sexual hormones could con-
tribute to the systemic low-grade pro-inflammatory
state, typical of elderly individuals [15]. The increase of
the circulating inflammatory mediators levels could also
derive from a constant low-grade activation of the immune
system caused by a chronic exposition to different types of
pathogens [19,20]. Some studies linked the exposition to
infections both the inflammatory state and the increased
risk of cardiac attack, ictus and cancer [21-24].
Consequently, research data indicate that during
ageing 1) the incapacity to preserve health, is caused
by the loss of physiologic homeostasis and that 2) the
base for the origin and the progression of chronic-
degenerative pathologies is the chronic inflammation
(Figure 1).
Implication of the hypothesis
As a consequences, it is in the physio-pathological
pathways that lead to chronic inflammation that it is to
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clinical biomarkers of homeostasis, for the prevention
and the treatment of chronic-degenerative diseases related
with ageing.
More specifically, using the methodologies of the study
of the system biology, the procedure consists in the indi-
viduation of biologic molecules, whose variations could
quantify the risk of losing the physiologic system
homeostatic capacity in the control of the inflammation
(Figure 4). These molecules have to be measurable in a
practical and no-invasive way, in all the following stages:
a) the normal state of health, that should be monitored
by biomarkers that indicate no-risk of pathology and
that we define of a type; b) the transient inflammatory
state, indicated by biomarkers linked to low-risk of
pathology, that we consider of b type; c) the chronic
inflammatory state, defined by biomarkers indicating a
high-risk of pathology, considered of c type. The scien-
tific rational is that, to be efficient in the prevention ofFigure 4 It is in the physio-pathological pathways that lead to chroni
the definition of clinical biomarkers of homeostasis for the preventio
procedure consists in the individuation of biologic molecules, whose variat
homeostatic capacity in the control of the inflammation. These molecules
following stages: a) in the normal state of health, in which we identify biom
the transient inflammatory state, where we define biomarkers of b type tha
state, in which it is possible to select biomarkers of c type that are indices of h
have to be predictive for the following passages to be efficient in the preven
condition (typical for the a type biomarkers), in which there is a homeostatic ba
(b type) where the restoration of this balance is still very probable, 3) and/or to
very improbable, while it is high the risk of progression toward degenerative pachronic-degenerative diseases, prognostic biomarkers
have to be predictive for the following passages: 1) from
the health physiologic condition, in which there is a
homeostatic balance in the inflammation control (typical
of the a type biomarkers), 2) to the transient inflamma-
tory state, where the restoration of this balance is still
very probable (b type biomarkers), 3) and/or to the
chronic inflammatory state, in which this recovery is
physiologically very improbable (c type biomarkers),
while it is relevant the risk of progression toward degen-
erative pathologies (Figure 4).
These biomarkers allow an early diagnosis and person-
alized therapeutic interventions, permitting a promising
change in the clinical practice and in the sanitary system
administration. They open to a large class of prevention
programs for these pathologies on the healthy popula-
tion, that are not yet available, thanks to their usefulness
in the identification of subjects that are still healthy,
but they are considered in risk of developing chronicc inflammation that it is to be researched the scientific ratio for
n and the treatment of chronic-degenerative diseases. The
ions could quantify the risk of losing the physiologic system
have to be measurable in a practical and no-invasive way, in all the
arkers of a type that are in this case indices of no-risk of disease; b) in
t are indices of low-risk of pathology; c) in the chronic inflammatory
igh-risk of disease. The scientific rational is that prognostic biomarkers
tion of chronic-degenerative diseases: 1) from the health physiologic
lance in the inflammation control, 2) to the transient inflammation
the chronic inflammation (c type) in which this recovery is physiologically
thologies.
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fact, justified the application of preventive sanitary
procedures, saving the actuation where they are not
motivated. Moreover they are prognostic for the pa-
tient stratification in clinic/therapeutic subgroups, be-
cause they also permit the quantification of the risk/
benefit related to a therapeutic treatment, allowing
the development of the personalized medicine that
could lead to a positive transformation of the clinical
strategies: the risk or benefit of the therapy is con-
nectable to the inability or ability of the specific treat-
ment to restore physiological homeostasis, that is
underlined by the changes of the individual biomarker
from b or c types to a type.
These aims could be reached identifying the molecules
that have the function of homeostatic biomarkers in the
control of the inflammation by evaluating two principal
groups, subdivided in internally homogeneous layers for
gender and age class: 1) the group of healthy subjects
and 2) the group of patients affected by chronic degen-
erative pathologies. In fact, the biomarkers of a healthyFigure 5 Biomarkers of homeostasis allow an early diagnosis
and personalized therapeutic interventions, permitting a
promising change in the clinical practice and in the sanitary
system administration. They open to a large class of prevention
programs for these pathologies on the healthy population, that are
not yet available, because they are suitable for the identification of
subjects that are still healthy, but with a high risk to develop this kind
of pathologies. On these individuals it is justified the application of
preventive sanitary procedures, saving the actuation where they are
not motivated.longevity have to be identified on healthy individuals,
but the biomarkers of the degeneration toward the path-
ology and of its progression have to be recognized on
patients, being the chronic-degenerative pathology a
pathological development of the basal inflammatory
process that begin their activity when the subject is still
healthy [25,26].
As a consequence, for the identification of these mole-
cules could be valid the following procedure: 1) To select
the biologic molecules with homeostatic biomarker cap-
acity in the control of inflammation, we need to study the
relationships between ageing and a healthy longevity in
the healthy population, comparing the age subgroups as
follow: the age subgroup in which the physiologic system
is healthy and where it has the optimal homeostatic func-
tioning (for example 18–55), with 1) the age subgroup in
which the physiologic system is still healthy, but its
functional capacity is negatively influenced by the ageing
effects (65–85), and also with 2) the age subgroup in
which the physiologic system is still healthy, but the
homeostatic capacity in the inflammation control is able
to stem the ageing effects and the age related pathologies
(>95). The aim is to discover the significant molecules
for this success: they are associated with better control of
inflammation and they allow to escape major age related
diseases. This could be useful in the definition of 1) the a
type biomarkers (prognostic for the homeostatic state and
no-risk of pathology) and 2) b type biomarkers (prognostic
for the transient inflammatory state, but also for the res-
toration possibility of the homeostatic condition and, then,
for low-risk of pathology) (Figure 6). These biomarkers
are usable in prevention intervention on the healthy popu-
lation, to select subject with low-risk of pathology and in
the evaluation of the relative risk/benefit related with the
specific therapy, in the selection of the most effective
treatment: the success or not of the treatment is connect-
able to the ability or inability to restore physiological
homeostasis, underlined by the ability or inability to deter-
mine a change of the homeostasis biomarkers in the
examined subject, from the b to the a type.
The subgroup of subjects older than 95 shows physio-
logic characteristics that support our hypothesis: it has
been demonstrated, in fact, that centenarians have better
chances to escape major age related diseases, including
cancer [27]. Autoptic studies clearly showed that in
centenarians the cause of death by chronic-degenerative
diseases was lower than expected [28] and was decreas-
ing in individuals over 99 years, compared to younger
ones [29]. Therefore, advancing age is known as the
most potent inductor of chronic disorders [30], but in old
individuals this prevalence does not increase, despite the
longer exposure to exogenous and endogenous factors
that could be able to cause pathologies. Centenarians are
characterized by a higher frequency of markers associated
Figure 6 The identification of molecules that have the function of homeostatic biomarkers. The study of the relationships between ageing
and a healthy longevity, in the healthy population comparing the age subgroups, could be useful in the definition of 1) a type biomarkers
(prognostic for the homeostatic state and of no-risk of pathology) and 2) b type biomarkers (prognostic for the transient inflammatory state, then
of the restoration possibility of the homeostatic condition and of low-risk of pathology). These biomarkers are usable in prevention intervention on the
healthy population and in the evaluation of the risk/benefit for the therapeutic selection of patients. On patients with chronic-degenerative pathologies
the procedure is to select the biologic molecules with homeostatic biomarker capacity in association with the losing of the inflammation control,
comparing the patient groups and the healthy individuals in internally homogeneous layers for gender and age, as upper described. The intent is to
define the significant molecules to select the c type of homeostatic biomarkers, indices of high-risk of disease, prognostic for the degeneration
toward pathology.
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capacity of centenarians to mount inflammatory re-
sponses appears to exert a protective effect towards
the development of those age-related pathologies having a
strong inflammatory pathogenetic component. Centenarians
seem to carry a genetic background with a peculiar
resistance to cancer which is also an anti-inflammatory
profile [31].
2) In order to select biologic molecules that can be
used as biomarkers in the loss of homeostasis and of the
inflammation control, we need to study the relationships
between ageing and the disease onset and progression: it
can be examined comparing patient groups and the
healthy individuals in internally homogeneous layers for
gender and age, as upper described, and for disease
stage. The intent is to define the significant molecules to
select the c type of homeostatic biomarkers, indices of
high-risk of disease, prognostic for the degeneration oftransient inflammatory state toward chronic inflamma-
tory state and the degenerative pathologies (Figure 6).
These biomarkers are usable in prevention intervention
on the healthy population, in order to select subject with
high-risk of pathology and to individuate the most effect-
ive treatment for the patient: the success or not of the
therapy is connectable to the ability or inability to restore
physiological homeostasis, then to the ability or inability
of the treatment to determine a change in the homeostasis
biomarkers in the examined individual from c to an a type,
considering a change toward the b type an indication of a
not idoneus therapy or not sufficient dosages.
For the definition of clinical "Biomarkers of Homeostasis"
the evaluation has to be necessarily made separately in
men and women
In the comprehension of the relationships between
ageing and 1) the healthy longevity and 2) the chronic-
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healthy longevity is related with a correct functioning of
the immune system [32-35] and that the pathology is gen-
erated by alterations of this one. In this contest it is also to
be considered that it is now assured the existence of a
gender dimorphism in the homeostatic control of the im-
mune system: men and women not only follow different
physiological pathways for the regulation of the immune
response, but these pathways, specific for each gender, also
suffer alterations during ageing and they predispose differ-
ently men and women to diseases [34] (Figure 7).
Clinical and experimental data show the presence of a
gender dimorphism in the immune response [36-39]:
male and female hormones influence the immune system
and they behave in opposite ways [40-42] (Figure 7). The
research has revealed that the gender is associated with
important incidence differences and with a prevalence of
differential age-related pathologies [43]. The sexual dimor-
phism is also a fundamental variable in the genetic of
longevity [44-46], indicating that men and women fol-
low different strategies for a healthy longevity success
(Figure 7).Figure 7 The Importance of the evaluation of the both gender, men a
different strategies to reach longevity. Clinical and experimental data sh
could not be evaluated in only one group, because the results would be n
dimorphism. It has been proved that the immunosenescence affects both
been demonstrated that female and male hormones act affecting in oppo
gender, male or female, is associated with relevant incidence and prevalen
variable in the genetic of longevity, indicating an important observation: mFor these reasons, in the selection of significant
molecules for the definition of clinical biomarkers of
homeostasis, the evaluation has to be necessary made
separately in men and women, as different independ-
ent groups.
For the study of the immune system homeostasis it is
relevant the cytokine survey
For the study of the immune system homeostasis it is
relevant the cytokine survey, being these substances
produced by cells of this system and regulating the trans-
position of the information between cells, thanks to the
activation of membrane receptors.
There is a growing consensus that the big part of
chronic pathologies of ageing are linked by a common
biology and that cellular senescence and the related secre-
tion of inflammatory mediators are common factors
[1,17,18]. It has become increasingly apparent that the cel-
lular senescence is a cellular stress response with a com-
plex phenotype and the senescence-associated secretory
phenotype entails the secretion of numerous proteases,
growth factors and cytokines which can have beneficial ornd women, as independent groups: men and women follow
ow that, when the immune system is involved, men and women
ot real, since in the immune response there is a natural gender
men and women, but it afflicts them differently. Furthermore, it has
site ways the immune system. The research has shown that the
ce of different types of age related diseases and it also is an important
en and women follow different strategies to reach longevity.
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text [1,17,18].
Moreover, recent studies [47-49] indicate, for the first
time, that the homeostatic equilibrium of the immune
response is regulated by cytokines that differ in men and
women, and that it is attributable to these differences
the different gender trend in the 1) immune response, 2)
the predisposition to diseases and 3) the therapeutic
response, opening to a new area for the translational
research at this level.
In fact these data show that the IFNy cytokine regu-
lates the male immune system homeostasis, while the
IL6 cytokine regulates the female one [47-49].
The above mentioned study [47] explains that a differ-
ent gender susceptibility and clinical course in diseases
is caused by different polarization of Th cell subsets
(Treg, Th17 and Th9) (Figure 8), determined by the in-
teractions of TGFβ, IL6, IFNy, IL10 and IL4 cytokine
pathways which vary between men and women [47].
These findings are supported by the studies, demonstrat-
ing that there is a reciprocal development relationship
between Treg, Th17 and Th9 cell subsets, for the reason
that: i) TGFβ triggers the expression of Foxp3 transcrip-
tion factor in naïve T cells, generating Treg cells, but ii)
IL6 inhibits the TGFβ driven expression of Foxp3; TGFβ
together with IL6 induce ROR-gt transcription factor,
triggering the developmental program of Th17 cells [46];Figure 8 Homeostasis is preserved and there are no differences betw
when the pathways of the gender specific cytokines (IFNγ and IL6) st
the regulation of the immune response is underlined by the evidence that
and women in the outcome of this response when the pathways of the ge
shown that the variations between pro- and anti-inflammatory cytokines co
discover, however, for the definition of suitable prognostic biomarkers, is th
by couple of pro- and anti- inflammatory cytokines that differ between me
in appropriate relationship each other and following different pathways inii) IL4 also inhibits TGFβ induction of Foxp3 expression,
but TGFβ together with IL4 induce the differentiation of
Th9 cells, which produce IL9 cytokine. Autoimmune
disease susceptibility in women, such as multiple scler-
osis, has been related with the influence of IL6 which
plays a key role in autoimmune diseases, since it is a T
cell differentiation switch factor for Tregs and Th17 cells
[48-51]. The greater probability in men of developing
the primary progressive multiple sclerosis form [52], on
the other hand, has been associated to the influence of
IFNy on Th9 cell inhibition: co-expression of IL-9 and
IL-17 was identified as a novel Th17 function in mediat-
ing autoimmune tissue destruction [53,54]. Recent re-
search on multiple sclerosis disease [55] confirms these
data, showing that a sexual dimorphism in autoimmune
diseases is the result of different cytokine pathways that
regulate the Th cell network homeostasis. Indeed, these
results indicate that: IL6 pathways are involved in Treg
cell imbalance and produce a worsening of the neuro-
logical deficit in both men and women groups of
multiple sclerosis patients, but the efficacy of IFNy-
treatment in the re-establishment of The cell network
balance (the immune response homeostasis) and delaying
the progression of neurological disability (the neurological
response homeostasis) is linked to the re-establish-
ment of IL6 pathway in women and of IFNγ pathway
in men [55].een men and women in the outcome of the immune response
ill normally work. The relevance of the gender specific differences in
homeostasis is preserved and there are no differences between men
nder specific cytokines (IFNγ and IL6) still normally work. It has been
uld influence the success of the immune response. The most relevant
e identification of “double prognostic biomarkers”: they are constituted
n and women and assure the success of the immune response varying
each gender.
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and IL6 pathway in women is the homeostatic biomarker
for the ascertainment of the immune system homeostasis
in the control of inflammatory state and, as a conse-
quence, it is also related to a healthy longevity (Figure 8).
It has been found that an altered state of these parameters
(Figure 9) could be a prognostic biomarker for the passage
from the healthy condition to the onset of an adenoma
and it could be an index of the progression toward colo-
rectal cancer [47], and for an aggravation of the neuro-
logical deficit in multiple sclerosis patients [55]. On the
other side, the good functioning of the IL10 cytokine regu-
late the restoration of the immune system to the rest state
homeostasis, after the response, both in men and women.
IL10 could be a prognostic biomarker of a healthy longev-
ity both in men and women, but only if IFNy and IL6 are
correctly functioning in the respective gender: if this con-
dition is not respected IL10 is a biomarker for the tumor
progression in both genders [47,55].
Ageing gender-specific clinical "Biomarkers of Homeostasis"
that could be used in interventional studies aimed at
improving health span
Inflammatory—anti-inflammatory cytokines serum levels
An applicable discovery for the definition of the upper
described clinical biomarkers of homeostasis has beenFigure 9 When alterations occur in the pathways of the gender-speci
in terms of disease development. This event is related to the impairmen
gender-specific cytokine pathways cause a pathologic polarization of speci
related to the different effects generated by IFNγ and IL6 cytokines, that ar
subtypes during the immune response.the identification of “double homeostatic biomarkers”,
defined as pro and anti-inflammatory cytokine couples,
specific for each sex, that control the immune system
homeostasis and the inflammatory process in the re-
spective gender by varying in an appropriate way
[47,55-58].
More specifically [52,55,56], in male peripheral blood
these variation are defined with a direct proportionality
(they both increase or decrease with the same trend,
positive or negative) that correlates the levels of
IFNγ―IL10, IL6―IL4 and IFNγ―IL4 cytokine cou-
ples (Figures 9 and 10); while in women these variations
in the peripheral blood interest the levels of IL6—IL10
couple with a relationship of inverse proportionality (the
increase of the first relates with the decrease of the sec-
ond and vice versa), while there is a direct proportional-
ity between IL6—IFNy couple (Figures 8, 9 and 10).
The thioredoxin 1 (Trx1) and the soluble molecule of
CD30 receptor (sCD30)
The study of the relationships between the redox state
and the functioning of the immune cells and the individ-
ual longevity, has a significant role for the comprehen-
sion of the ageing process finalized to a healthy ageing
[57-61]: one of the cause responsible for the differential
gender susceptibility to pathologies is the different capacityfic cytokines, the consequences for men and women are different,
t of the immune system homeostasis, because the alterations of
fic T cell types, different for each gender. The reason of this fact is
e present in the cellular environment, on the generation of Th cell
Figure 10 The variations between pro- and anti-inflammatory cytokines could influence the success of the immune response. The most
relevant discover, however, for the definition of suitable prognostic biomarkers, is the identification of “double prognostic biomarkers”: they are
constituted by couple of pro- and anti- inflammatory cytokines that differ between men and women and assure the success of the immune response
varying in appropriate relationship each other and following different pathways in each gender. The early evolution of the immune response is
influenced by the positive correlation between the production of IFNγ-IL10 and IL6-IL4 in men, and the negative one between IL6-IL10 in women. The
evolution of the late response is also influenced by the positive correlation between the production of IFNγ-IL4 in men and IL6-IFNγ in women. More
specifically the “double prognostic biomarkers” for men are related by direct proportionality (they both increase or decrease together with the same
trend, both positive or negative) between the IFNγ―IL10, IL6―IL4 and IFNγ―IL4 cytokine levels; while they are interconnected in women by an
inverse proportionality (an increase of the first correspond to a decrease of the second and vice versa) between the IL6―IL10 cytokine levels, and with a
direct proportionality between the IL6―IFNγ cytokines. These variations between the couple of inflammatory and anti-inflammatory cytokines, specific
for each gender, are to be considered “double biomarkers” gender-specific, in the valuation of relationships between ageing and a healthy longevity.
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oxidative stress [62,63].
These results show that the cells of both sexes are very
different in terms of reactive oxygen species (ROS) pro-
duction and of their susceptibility to the oxidative stress
and it could constitute a new promising area of research.
Oxygen metabolism could lead to the production of
ROS in each type of cells, also in the immune system
ones: in fact they present antioxidant compounds and
enzymes (as glutathione and thioredoxin reductase)
[64,65], that are able to neutralize ROS and preserve the
oxidative cellular balance. However, the activity of
ROS seems to be regulated differently in men andwomen and it could be directly influenced by sexual
hormones [63].
These results indicate, then, that the homeostatic bio-
markers are selectable in the peripheral blood factors
constituting a correlation between the redox and the
immune system and that are involved in multiple cellular
processes, as proliferation, cellular cycle and the pathways
of death and survival signals [66,67].
The Thioredoxin system (Trx) is a fundamental physio-
logic regulator of the redox factors for the immune res-
ponse [67-69]. Trx1, a protein containing selenocisteine,
catalyzes the NADPH-dependent reduction of Trx1 reduc-
tase (TRrx1) and several other oxidized cellular proteins
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cellular signals, activating specific transcriptional fac-
tors that regulate the decode in the nucleus of the
genes that produce substances for the defense of the
cell against the ROS, that have induced the oxidative
stress condition [71-74].
As a consequence, in order to select the clinical
homeostatic biomarkers related with the inflammation
control, it is clinically relevant to underline that the
CD30 receptor (RCD30 on the immune cell membrane
(T and B cells, monocytes, dendritic cells, NK, eosino-
phils and granulocytes), is a specific Trx1 receptor [75].
There are indications that the physiological function of
RCD30 could behave as a signal transducing molecule.
The interaction between RCD30 and its ligand (CD30L)
on the T and B activated cell, monocytes, neutrophils,
eosinophils induces the rapid activation of genetic tran-
scriptional factors as JunN-kinase and NF-kB [76,77]. It
has been shown that RCD30 signals induce and regulate
the integrated lymphocytary genetic expression of mole-
cules that have a cytotoxic effect, they control lympho-
nodal traffic, proliferation and apoptosis [78]. RCD30 is
a member of the TNF/NGF receptor super-family, it is
generally defined as a molecule that mediates the regula-
tion signals.
The results [77,79-82] underlined the importance of its
physiopathologic function, clarifying that the interaction
between RCD30 and sCD30 (released when RCD30
interact whit its ligand CD30L), controls the physiologicFigure 11 The functional link between Trx1 and CD30 is a very impor
big potentiality of these elements as clinical diagnostic and therapeu
Trx1, sCD30 is also able to influence the CD30R capacity to mediate the ac
healthy longevity, thanks to the inhibition of the binding between CD30L a
stoichiometric structure of RCD30; sCD30 makes the same function binding
affinity. For these reasons they have both to be considered for the use of t
and sCD30 could both influence the capacity of CD30R to mediate the acthomeostasis in the immune and in the neurologic system
by regulating the functions of monocytes and dendritic
cells, mature and immature, to direct the T-helper cell
(Th) differentiation in the respective subtypes (Th1, Th2,
Th3, Th9 and Th17). These results explain, then, that the
functional link between Trx1 and sCD30 is a very import-
ant step in the physiologic homeostasis and it underlines
the big potentiality of these elements as clinical diagnostic
and therapeutic targets (Figure 11).
Indeed, similarly to Trx1, sCD30 is able to influence
the RCD30 capacity to mediate the activation of intra-
cellular signals, through the inhibition of the binding
between CD30L and RCD30: Trx1 makes this function
catalytically, modifying the stoichiometric structure of
RCD30 [70]; sCD30 makes this function blocking the
binding site of CD30L, with which it has a strong affinity
[82]. During inflammatory situations RCD30 is strongly
expressed on the immune cells and, as a consequence,
there is an increase of the sCD30 levels that is released
in the extracellular environment and of the inhibition of
the RCD30 signals [82].
The results have, also, underlined that the sCD30 level
variations in the cellular environment (serum, tissue or
tumoural microenvironment) could be used as a bio-
marker of the immune system homeostasis and of the
benefit or risk of therapeutic response [77,79-81,83,84]:
the sCD30 level within the normal physiological ranges
is index of the immune system homeostasis and of the
therapeutic benefit, while a significant increase of thetant step in the physiologic homeostasis and it underlines the
tic targets. The results of the research explained that in addition to
tivation of intracellular signals for immune system homeostasis and
nd RCD30: Trx1 makes this function catalytically, modifying the
and blocking the binding site of CD30L, with which it has a strong
he RCD30 as immunological and therapeutic biomarkers, because Trx1
ivation of intracellular signals.
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logical deficit and of the therapeutic risk.
For these reasons Trx1 and sCD30 have both to be
considered as homeostatic biomarkers. Research indicate
that changes of the Trx1 and sCD30 levels are functional
extracellular biomarkers of the new Trx1/CD30 target
(Figure 11), while the Treg/Th1/Th9/Th17 cytokines
levels are functional biomarkers of the intracellular path-
ways for the prognostic and diagnostic/therapeutic
stratification of patients [77,85-87].
Further clarification of the regulation pathways by
means of Trx1 and sCD30 molecules, could lead to non-
invasive treatments for the reestablishment of the im-
munological homeostasis and therapeutic response
benefit. The potential of Trx1 and CD30 as single targets
and biomarkers has already been described in literature,
but the innovative hypothesis is in the combined use of
Trx1 and sCD30 as a double target/biomarker (Trx1—
sCD30) [84]. The rational of this hypothesis is that the
Trx1—sCD30 target/biomarker concretize the diagnostic
and therapeutic possibility to intervene on the multiple
pathways of the redox and the immune system, opening
to new and important perspectives for the degenerative
diseases related with the oxidative stress, as tumors [84]
and ageing [56].
Indication for an "Evaluation System"
It consider different possibilities (Figure 12):
1. The levels of Trx1-sCD30 molecules and of
gender-specific "cytokine couples" are within the
normal physiological ranges: this condition is
considered an a type biomarker, that is prognostic
for the homeostatic state of the normal health
condition. This is a biomarker of: a) subjects with
no-risk of pathology in prevention strategies on
healthy people; b) effective treatments, that are
capable of restoring the physiological homeostasis in
the control of inflammation, evidenced by the
change of the patient's biomarker from the type
"b" or "c" to the type "a".
2. The levels of Trx1-sCD30 molecules in both gender
could be or not in the normal physiological ranges,
but the level variations of gender "cytokine couples"
(for example IFNy—IL10, IL6—IL4 and IFNy—IL4
in men) are out of the normal physiological ranges.
In this particular case they change in a direction that
agrees with the negative or positive trend (in this
case positive) of their correlation in the normal
healthy state, which is biomarker of homeostasis of
b type. This is prognostic for the passage from the
normal health condition of the homeostatic state,
to transient inflammatory state. It indicates the
restoration possibility of the homeostasis and it is anindex of: a) subjects with low-risk of pathology in
prevention strategies on healthy people; b) patient
treatments that are not adequately effectives
because they are capable of restoring the physiological
homeostasis thanks to the control of the inflammation,
but they have not yet restored the inflammatory
base condition: this situation is evidenced by the
no-change of the type "b" or "c" into the type "a"
of the patient's biomarker.
3. The levels of Trx1-sCD30 molecules in both gender
are not in the normal physiological ranges and
variation of the levels of the cytokine couples
(for example IFNy—IL10, IL6—IL4 and IFNy—IL4
in men) exit from the normal physiological rages,
but in an opposite (in this case negative) direction in
relationship with the normal health condition: this is
considered a biomarker of the irreversible loss of
homeostasis in the inflammation control, c type.
This is prognostic for the passage from the
transient inflammatory state and the restoration
possibility of the control of inflammation, to the
chronic inflammatory state and loss of physiological
control of inflammation, in which its restoration is
physiologically improbable. It is an index of: a)
subjects with high-risk of pathology in prevention
strategies on healthy people; b) patient treatments
that are not effectives, because it is incapable of
restoring the physiological homeostasis in the
control of inflammation, that is evidenced by the
no-change of the type "c" into the type "a" of
the patient's biomarkers.
Conclusions
The new research perspectives for the definition of
“clinical biomarkers of homeostasis”, that could be prog-
nostic for the risk of our physiologic system of losing the
homeostatic capacity in the control of the inflammation,
have a concrete and immediate relevance in the preven-
tion of chronic-degenerative pathologies related with
ageing. In fact, these biomarkers could lead to benefits
in the improvement of a) the heath quality and lifespan
for the elderly population, that is progressively increasing,
and then b) the related budgets of the sanitary system
administration.
The proposed clinical biomarkers (Figure 12) could be
a real tool for the evaluation of the above homeostatic
capacity, for the following reasons:
 The statistic methodologies of the system biology
study have been used for their selection: they are
analytic advanced methods used for the evaluation
of the physiological network, amply consolidated
and approved by the scientific community for the
biomedical research [85-87]. This methodology,
Figure 12 Double biomarkers of homeostasis to evaluate the ability of our physiological system to control the inflammation and
preserve the state of health: "Evaluation System". The double biomarkers are of: 1) a type if the levels of Trx1—sCD30 molecules in both
gender are within the normal physiological ranges and the levels of IFNy—IL10, IL6—IL4 and IFNy—IL4 for men are in the physiological ranges
and they are related by a direct proportionality: their amounts may be equal, above or under the mean and they both increase or decrease in
the same sense, positive or negative; the levels of IL6—IFNy and IL6—IL10 for women are in the physiological ranges, and they are respectively
related by direct and inverse proportionality: their quantities are equal, above or under the mean, they both increase or decrease with the same
verse, positive or negative, in case of direct proportionality, and in inverse verse, positive the first and negative the second or vice versa, in case
of inverse proportionality; 2) b type if the levels of Trx1—sCD30 molecules in both gender are or are not in the normal physiological ranges and
the levels of IFNy—IL10, IL6—IL4 and IFNy—L4 in men are not in the physiologic ranges, but they are still related by the same direct
proportionality, corresponding to the homeostatic condition; the levels of IL6—IL10 and IL6—FNy in women are not in the physiological ranges,
but they are still related by the same proportionalities, inverse and direct, corresponding to the homeostatic condition; 3) c type if levels of
Trx1—sCD30 molecules in both gender are not in the normal physiological ranges and the levels of IFNy—IL10, IL6—IL4 and IFNy—IL4 in men
are not in the physiological ranges and they are not related with the same direct proportionality of the homeostatic state, but they are characterized
by an inverse proportionality; the levels of IL6—IFNy and IL6—IL10 in women are not in the physiological ranges and they are not related by the
same inverse and direct proportionality of the homeostatic state, but the first couple by an inverse proportionality and the second by a direct one.
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the multiple component networks, comprehend the
dynamic and functional evaluation of the
relationships of all the variables (immune, genetic
and clinical data) of the physiologic network in
study. The analysis of all this amount of data is
performed by “data driven, computational models”,
that are mathematic models based on multiple
experimental results: data are analyzed by factorial
analysis and only the significant parameters are
underlined.
 The "couple structuring" of the molecules, related
with the proposed “homeostatic biomarkers”, is one
of the determinant characteristics for the realprognostic capacity of these biomarkers. In fact
the direct/indirect relationship between the
levels of couples of molecules is a dynamic
biomarker of the range of the homeostatic balance
capacity of the physiologic system in the control
of the inflammation. The same function could
not be possible if the biomarker is constituted
from only a molecule.
 The upper mentioned “double homeostatic
biomarkers” are both, the same in both sexes
(Trx1—sCD30) [84] and also gender-specific
(cytokines couples) [52,55-58]. These are defined
by couple of pro and anti-inflammatory cytokines
of different type for men and women, that vary in
Berghella et al. Immunity & Ageing 2014, 11:3 Page 14 of 16
http://www.immunityageing.com/content/11/1/3an appropriate way controlling the homeostasis
of the immune system and the inflammation
in the respective genders: the sexual dimorphism
of the immune response is one of the most
relevant problems that have to be considered
evaluating differences between men and women
in the disease susceptibility and the therapeutic
response.
 Finally, inflammatory and anti-inflammatory
cytokines as well as sCD30 and Trx1 molecules are
of basilar importance for the homeostasis control
of the immune response and the inflammatory
state: the interaction between the immune system
and the redox one is very significant for this aim,
because a key involvement of these two systems is
concretely underlined by the relationship between
the redox state, immune cell functioning and
individual longevity.
For these reasons, “double homeostatic biomarkers”
open to prevention programs for chronic-degenerative
diseases on the healthy population that are not yet exist-
ent: they are suitable for the selection of healthy subjects
with risk of developing this kind of pathologies. On
these individuals is justified the application of preventing
sanitary procedure, avoiding the application on other
subjects when not motivated. They are also prognostic
for the stratification of patients in clinic/therapeutic sub-
groups, allowing the quantification of the risk/benefit for
the specific treatment, the selection of the most effective
patient treatment and the development of a personalized
medicine that will lead to positive transformation of the
clinical strategies.
Further study are now required to verify the potential
benefits in predictive medicine, that will validate or refute
this new hypothesis.Competing interests
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